(6 years, 6 months ago)
Commons ChamberI am not the all-seeing eye, so all I can say is yes, I will look very carefully at the issue that my hon. Friend raises.
(7 years, 2 months ago)
Commons ChamberObviously I would be deeply concerned if patients were losing their sight due to treatment not happening in a timely way. Dudley clinical commissioning group tells me that it has already made funding available for Eylea following consideration of the NICE evidence summary issued in June 2016. This is the first drug that we have appraised through the new fast-track process for treatments that demonstrate clear cost-effectiveness. Patients will have routine access to Eylea from 1 December should the guidance remain unchanged. Of course, I would be happy to meet the hon. Gentleman and his constituent.